Multiple Myeloma

Experts from leading institutions debate the latest advances in multiple myeloma.

Following the 2022 ASH Annual Meeting and Exposition, Peter Voorhees, MD; Amrita Krishnan, MD; and Josh Richter, MD, participated in a rapid-fire question-and-answer 2-Minute Drill program, hosted by CancerNetwork®. Topics ranged from most exciting data in blood cancer, as well as what research needs more follow-up.

Ravi Vij, MD, MBA, suggested that 4-drug regimens may be a new standard for frontline therapy in newly diagnosed multiple myeloma, as oncologists await trial readouts from ongoing clinical trials.

Ravi Vij, MD, MBA, offered additional information about the use of various regimens aimed to treat patients with high-risk, newly diagnosed multiple myeloma, that were read out at the 2022 ASH Annual Meeting.

Ravi Vij, MD, MBA, discussed updated analyses of the phase 3 SWOG S0777 trial, supporting the use of bortezomib, lenalidomide, and dexamethasone in untreated patients with multiple myeloma who do not plan on receiving immediate autologous stem cell transplant.

Ken Shain, MD, PhD, pinpoints the critical, lingering gaps in patient access to cellular immunotherapies in multiple myeloma.

Ken Shain, MD, PhD, provides an overview of developments on the horizon in multiple myeloma.

Ken Shain, MD, PhD, spoke about the dramatic impact of novel immunotherapies in the multiple myeloma treatment landscape, as well as other updates from the 2022 ASH Annual Meeting and Exposition.

Ken Shain, MD, PhD, discussed some of the research in multiple myeloma that was featured in a recent FaceOff program, and how these recent advances may change the standard of care.

The FDA has now requested that the manufacturer of melphalan flufenamide withdraw the multiple myeloma drug from the United States market months after the drug developer rescinded a letter voluntarily withdrawing the therapeutic.

Patients in China diagnosed with high-risk neuroblastoma can now receive treatment with naxitamab-gqgk, which was recently given the greenlight by the National Medical Products Administration.

Before closing out their review on the management of multiple myeloma, panelists consider disparities in care and share how these barriers are being addressed.

A comprehensive review of novel therapy being investigated in the setting of relapsed/refractory multiple myeloma to expand the bispecific antibody and CAR T-cell therapy armamentarium.

The panel shares some unmet needs in the multiple myeloma treatment landscape and exciting developments on the horizon.

The FDA has received a biologic license application for talquetamab to treat relapsed/refractory multiple myeloma.

Melissa Alsina, MD, shares her excitement for an upcoming program wherein she and other key opinion leaders from the Moffit Cancer Center review updated data and optimal treatment strategies in the setting of multiple myeloma.

BCMA/CD19 dual-targeting FasTCAR-T Cells resulted in an overall response rate of 100% among patients with multiple myeloma, with all evaluable patients showing MRD negativity to 12 months.

Updated findings from the phase 2 CARTITUDE-2 trial highlighted the promising efficacy of ciltacabtagene autoleucel in patients with relapsed or refractory multiple myeloma following early relapse.

The final analysis from the phase 2 DREAMM-2 study found continued efficacy in patients who had relapsed/refractory multiple myeloma.

A triple-class exposed population of patients diagnosed with relapsed or refractory multiple myeloma experienced progression-free survival benefit following treatment with belantamab mafodotin with pomalidomide and dexamethasone.

A quadruplet regimen with daratumumab as its base was found to improve health related quality of life in patients with transplant-eligible, newly diagnosed multiple myeloma.

Efficacy and safety findings were positive in the phase 1/2 CC-92480-MM-001 trial when mezigdomide was added to dexamethasone in patients with heavily pretreated multiple myeloma.

The findings, according to the lead study author, demonstrate that treatment with forimtamig delivered intravenously or subcutaneously may elicit long-term responses in patients with relapsed or refractory multiple myeloma.

Patients with penta-or triple-class refractory multiple myeloma who have not received prior B-cell maturation antigen therapy saw an improved objective response rate when elranatamab was given.

Findings from the phase 1b MajesTEC-2 trial indicated that teclistamab in combination with daratumumab and lenalidomide demonstrated potential for deep and durable responses in relapsed or refractory multiple myeloma.